Drug Information Rounds

de Feyter PJ de Jaegere PT Serruys PW . Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994; 127: 643–51.

Vaitkus PT Laskey WK . Efficacy of adjunctive thrombolytic therapy in percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994; 24: 1415–23.

Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217–25.

Ambrose JA . Thrombolysis as an adjunct to angioplasty. Am J Cardiol 1993; 72: 34G–39G.

Neuhaus KL Zeymer U . Prevention and management of thrombotic complications during coronary interventions. Combination therapy with antithrombins, and antiplatelets, and/or thrombolytics: Risks and benefits. Eur Heart J 1995; 16: 63–7.

Ambrose JA Almeida OD Sharma SK Torre SR Marmur JD Israel DH Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina: Results of the TAUSA Trial. Circulation 1994; 90: 69–77.

Schachinger V Kasper W Zeiher AM . Adjunctive intracoronary urokinase therapy during percutaneous transluminal coronary angioplasty. Am J Cardiol 1996; 77: 1174–8.

Schofer J Krebber HJ Bleifeld W Mathey DG . Acute coronary artery occlusion during percutaneous transluminal coronary angioplasty: Reopening by intracoronary streptokinase before emergency coronary artery surgery to prevent myocardial infarction. Circulation 1982; 66: 1325–31.

Suryapranata H de Feyter PJ Serruys PW . Coronary angioplasty in patients with unstable angina pectoris: Is there a role for thrombolysis? J Am Coll Cardiol 1988; 12: 69A–77A.

de Feyter PJ van den Brand M Jaarman GJ van Domburg R Serruys PW Suryapranata H Acute coronary artery occlusion during and after percutaneous coronary angioplasty: Frequency, prediction, clinical course, management, and follow-up. Circulation 1991; 83: 927–36.

Gulba DC Daniel WG Simon R Jost S Barthels M Amende I Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1990; 16: 563–8.

Clinical experience with intracoronary tissue plasminogen activator: Results of a multicenter registry: Intracoronary t-PA registry investigators. Cathet Cardiovasc Diagn 1995; 34: 196–201.

Goudreau E DiSciascio G Vetrovec GW Chami Y Kohli R Warner M Intracoronary urokinase as an adjunct to percutaneous transluminal coronary angioplasty in patients with complex coronary narrowing or angioplasty induced complications. Am J Cardiol 1992; 69: 57–62.

Verna E Repetto S Boscarini M Onofri M Qing LG Binaghi G . Management of complicated coronary angioplasty by intracoronary urokinase and immediate re-angioplasty. Cathet Cardiovasc Diagn 1990; 19: 116–22.

Schieman G Cohen BM Kozina J Erickson JS Podolin RA Peterson KL Intracoronary urokinase for intracoronary thrombus accumulation complicating percutaneous transluminal coronary angioplasty in acute ischemic syndromes. Circulation 1990; 82: 2052–60.

Vaitkus PT Herrmann HC Laskey WK . Management and immediate outcome of patients with intracoronary thrombus during percutaneous transluminal coronary angioplasty. Am Heart J 1992; 124: 1–7.

Lincoff AM Popma JJ Ellis SG Hacker JA Topol EJ . Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992; 19: 926–35.

Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330: 956–61.

Topol EJ Califf RM Weisman JF Ellis SG Tcheng JE Worley S Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994; 343: 881–6.

Anderson VH Revana M Rosales O Brannigan L Stuart Y Weisman H Intravenous administration of monoclonal antibody to the platelet GP IIb/IIIa receptor to treat abrupt closure during coronary angioplasty. Am J Cardiol 1992; 69: 1373–6.

Cardinale V Chi JC , eds. Drug topics red book. Montvale, NJ: Medical Economics Co., Inc., 1997.

Blaser MJ . Helicobacter pylori and the pathogenesis of gastrointestinal inflammation. J Infect Dis 1990; 161: 626–33.

Kuipers EJ Uyterlinde AM Pena AS Roosendall R Pals G Nelis GF Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345: 1525–8.

Carlson SJ Yokoo H Vanagunas A . Progression of gastritis to monoclonal B-cell lymphoma with resolution and recurrence following eradication of Helicobacter pylori. JAMA 1996; 275: 937–9.

Hansson LE Nyren O Hsing AW Bergstrom R Josefsson S Chow WH The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996; 335: 242–9.

NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65–9.

Bourke B Jones N Sherman P . Helicobacter pylori and peptic ulcer disease in children. Pediatr Infect Dis J 1996; 15: 1–13.

Khulusi S Badve S Patel P Lloyd R Marrero JM Finlayson C Pathogenesis of gastric metaplasia of the human duodenum: Role of Helicobacter pylori, gastric acid, and ulceration. Gastroenterology 1996,110: 452–8.

Roggero E Zucca E Pinotti G Pascarella A Capella C Savio A Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995; 122: 767–9.

van Zanten Veldhuyzen S Sherman P . Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: A systematic overview. Can Med Assoc J 1994; 150: 177–85.

Chiba N Rao BV Rademaker JW Hunt RH . Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716–27.

Labenz J Gyenes E Ruhl G Borsch G . Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer diseases: A prospective, randomized, and controlled study. Gut 1993; 34: 1167–70.

Logan R Gummett P Hegarty B Walker M Baron J Misiewcz J . Clarithromycin and omeprazole for Helicobacter pylori (letter). Lancet 1992; 340: 239.

Drumm B . Helicobacter pylori in the pediatric patient. Gastroenterol Clin North Am 1993; 22: 169–82.

Mitchell H Bohane T Tobias V Bullpitt P Daskalopoulos G Carrick J Helicobacter pylori infection in children: Potential clues to pathogenesis. J Pediatr Gastroenterol Nutr 1993; 16: 120–5.

MaCarthur C Saundes N Feldman W . Helicobacter pylori, gastrointestinal disease, and recurrent abdominal pain in children. JAMA 1995; 273: 729–34.

Kilbridge P Dahms B Czinn S . Campylobacter pylori-associated gastritis and peptic ulcer disease in children. Am J Dis Child 1988; 142: 1149–52.

Oderda G Dell'Olio D Morra I Ansaldi N . Campylobacter pylori gastritis: Long term results of treatment with amoxycillin. Arch Dis Child 1989; 64: 326–9.

Yeung C Fu K Yuen K Ng W Tsang T Branicki F Helicobacter pylori and associated duodenal ulcer. Arch Dis Child 1990; 65: 1212–6.

Oderda G Holton J Altare F Vaira D Ainley C Ansaldi N . Amoxycillin plus tinidazole for Campylobacter pylori gastritis in children: Assessment by serum IgG antibody, pepsinogen I, and gastrin levels. Lancet 1989; 1: 690–2.

Oderda G Vaira D Dell'Olio D Holton J Forni M Altare F Serum pepsinogen I and gastrin concentrations in children positive for Helicobacter pylori. J Clin Pathol 1990; 43: 762–5.

Oderda G Vaira D Ainley C Holton J Osborn J Altare F Eighteen month follow up of Helicobacter pylori positive children treated with amoxycillin and tinidazole. Gut 1992; 33: 1328–30.

Drumm B Sherman P Chiasson D Karmal I Cutz E . Treatment of Campylobacter pylori-associated antral gastritis in children with bismuth subsalicylate and ampicillin. J Pediatr 1988; 113: 908–12.

Israel D Hassall E . Treatment and long-term follow-up of Helicobacter pylori associated duodenal ulcer disease in children. J Pediatr 1993; 123: 53–8.

Thomas J Whatmore A Barer M Eastham E Kehoe M . Serodiagnosis of Helicobacter pylori infection in childhood. J Clin Microbiol 1990; 28: 2641–6.

Mahony M Wyatt J Littlewood J . Management and response to treatment of Helicobacter pylori gastritis. Arch Dis Child 1992; 67: 940–3.

De Giacomo C Fiocca R Villani L Lisato L Licardi G Diegoli N Helicobacter pylori infection and chronic gastritis: Clinical, serological, and histologic correlations in children treated with amoxicillin and colloidal bismuth subcitrate. J Pediatr Gastroenterol Nutr 1990; 11: 310–6.

Pickering LK Feldman S Ericsson CD Cleary TG . Absorption of salicylate and bismuth from a bismuth subsalicylate-containing compound (Pepto-Bismol). J Pediatr 1981; 99: 654–6.

DuPont HL . Bismuth subsalicylate in the treatment and prevention of diarrheal disease. Drug Intell Clin Pharm 1987; 21: 687–93.

Bearman S . The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005–20.

McDonald GB Hinds MS Fisher LD Schoch HG Wolford JL Banaji M Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993; 118: 255–61.

Grochow LB Jones RJ Brundrett RB Braine HG Chen TL Saral R Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55–61.

Or R Nagler A Shpilberg O Elad S Naparstek E Kapelushnik J Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplant patients. Transplantation 1996; 61: 1067–71.

Rowe JM Ciobanu N Ascensao J Stadtmauer EA Weiner RS Schenkein DP Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG). Ann Intern Med 1994; 120: 143–58.

Clift RA Bianco JA Appelbaum FR Buckner CD Singer JW Bakke L A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic bone marrow transplantation (abstract). Blood 1993; 82: 2025.

Deleve L . Dacarbazine toxicity in murine liver cells: A model of hepatic endothelial injury and glutathione defense (abstract). J Pharmacol Exp Ther 1994; 286: 1261.

Holler E Kolb HJ Moller A Kempeni J Liesenfeld S Pechumer H Increased serum levels of tumor necrosis factor-alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011–6.

Shulman H Hinterberger W . Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197–214.

McDonald GB Sharma P Matthews DE Shulman HM Thomas ED . Veno-occlusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116–22.

McDonald GB Sharma P Matthews DE Shulman HM Thomas ED . The clinical course of 53 patients with venoocclusive disease of the liver after marrow transplantation. Transplantation 1985; 39: 603–8.

Jones RJ Lee KS Beschorner WE Vogel VG Grochow LB Braine HG Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778–83.

Clift RA Buckner CD Thomas ED Bensinger WI Bowden R Bryant E Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036–43.

Dix SP Wingard JR Mullins RE Jerkunica I Davidson TG Gilmore CE Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225–30.

Schuler U Schroer S Kuhnle A Blanz J Mewes K Kumbier I Busulfan pharmacokinetics in bone marrow transplant patients: Is drug monitoring warranted? Bone Marrow Transplant 1994; 14: 759–65.

Klaesson S Ringden O Ljungman P Aschan J Hagglund H Winiarski J . Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver? Transplantation 1995; 60: 1225–30.

Ward A Brogden RN Heel RC Speight TM Avery GS . Ursodeoxycholic acid: A review of its pharmacological properties and therapeutic efficacy. Drugs 1984; 27: 95–131.

Poupon RE Balkau B Eschwege E Poupon R . A multicenter trial of ursodiol for treatment of primary biliary cirrhosis. UDCA-PBC study group. N Engl J Med 1991; 324: 1548–54.

Podda M Ghezzi C Battezzati PM Bertolini E Crosignani A Petroni ML Ursodeoxycholic acid for chronic liver disease. J Clin Gastroenterol 1988; 10 (Suppl 2):S25–31.

Essell JH Thompson JM Harman GS Halvorson RD Snyder MJ Callander NS Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1992; 10: 367–72.

Product information. Actigall (ursodiol). Summit, NJ: Ciba-Geigy Corp., 1992.

Essell J Schroeder M Thompson J Harman G Halvorson R Callander N . A randomized double-blind trial of prophylactic ursodeoxycholic acid (UDCA) vs placebo to prevent veno-occlusive disease of the liver (VOD) in patients undergoing allogeneic bone marrow transplantation (BMT) (abstract). Blood 1994; 84 (Suppl 1):250a.